Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Significant Decrease in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 8,701 shares, a drop of 36.0% from the September 30th total of 13,598 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 35,468 shares, the short-interest ratio is currently 0.2 days.

Aspire Biopharma Trading Down 2.3%

NASDAQ ASBP traded down $0.19 during trading on Monday, reaching $7.92. The company’s stock had a trading volume of 3,928 shares, compared to its average volume of 266,134. The firm has a market capitalization of $11.09 million, a price-to-earnings ratio of -0.11 and a beta of 0.17. The firm has a 50 day moving average price of $8.55 and a 200 day moving average price of $17.94. Aspire Biopharma has a 12 month low of $3.31 and a 12 month high of $468.00.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Aspire Biopharma presently has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma, Inc is a clinical-stage biopharmaceutical company developing orally administered therapies using a proprietary fast-dissolving tablet and sublingual delivery platform. The company’s technology is designed to deliver active ingredients through the tissues beneath the tongue, potentially allowing rapid absorption while reducing reliance on the gastrointestinal tract and first-pass metabolism.

Aspire’s lead development program has focused on an orally dissolvable epinephrine product intended for the emergency treatment of severe allergic reactions, including anaphylaxis.